Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.

Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ.

Br J Cancer. 2014 Apr 15;110(8):1977-84. doi: 10.1038/bjc.2014.91. Epub 2014 Feb 20.

2.

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.

Fang DD, Cao J, Jani JP, Tsaparikos K, Blasina A, Kornmann J, Lira ME, Wang J, Jirout Z, Bingham J, Zhu Z, Gu Y, Los G, Hostomsky Z, Vanarsdale T.

Front Med. 2013 Dec;7(4):462-76. doi: 10.1007/s11684-013-0270-6. Epub 2013 Jul 2.

PMID:
23820871
3.

NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.

Hunter JE, Willmore E, Irving JA, Hostomsky Z, Veuger SJ, Durkacz BW.

Oncogene. 2012 Jan 12;31(2):251-64. doi: 10.1038/onc.2011.229. Epub 2011 Jun 27.

4.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.

J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.

PMID:
21183737
5.

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ.

Br J Cancer. 2010 Nov 9;103(10):1588-96. doi: 10.1038/sj.bjc.6605946. Epub 2010 Oct 26.

6.

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ.

Clin Cancer Res. 2010 Apr 15;16(8):2344-51. doi: 10.1158/1078-0432.CCR-09-2758. Epub 2010 Apr 6.

7.

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC.

Clin Cancer Res. 2009 Feb 15;15(4):1241-9. doi: 10.1158/1078-0432.CCR-08-1095. Epub 2009 Jan 27.

8.

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, Webber SE, Curtin NJ.

Mol Cancer Ther. 2007 Mar;6(3):945-56.

9.

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

Tikhe JG, Webber SE, Hostomsky Z, Maegley KA, Ekkers A, Li J, Yu XH, Almassy RJ, Kumpf RA, Boritzki TJ, Zhang C, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR.

J Med Chem. 2004 Oct 21;47(22):5467-81.

PMID:
15481984
10.

Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.

White AW, Curtin NJ, Eastman BW, Golding BT, Hostomsky Z, Kyle S, Li J, Maegley KA, Skalitzky DJ, Webber SE, Yu XH, Griffin RJ.

Bioorg Med Chem Lett. 2004 May 17;14(10):2433-7.

PMID:
15109627
11.

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, Newell DR.

Clin Cancer Res. 2004 Feb 1;10(3):881-9.

12.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.

PMID:
14709739
13.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ.

Clin Cancer Res. 2003 Jul;9(7):2711-8.

14.

Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z, Webber SE, Eastman BW, Almassy R, Li J, Curtin NJ, Newell DR, Calvert AH, Griffin RJ, Golding BT.

J Med Chem. 2003 Jan 16;46(2):210-3.

PMID:
12519059
15.

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z.

J Med Chem. 2002 Nov 7;45(23):4961-74.

PMID:
12408707
16.

Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.

White AW, Almassy R, Calvert AH, Curtin NJ, Griffin RJ, Hostomsky Z, Maegley K, Newell DR, Srinivasan S, Golding BT.

J Med Chem. 2000 Nov 2;43(22):4084-97.

PMID:
11063605
17.

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR.

Clin Cancer Res. 2000 Jul;6(7):2860-7.

18.

Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1.

Dantzer F, de La Rubia G, Ménissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V.

Biochemistry. 2000 Jun 27;39(25):7559-69.

PMID:
10858306
19.

The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor.

Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Margosiak S, Dagostino E, Hostomska Z.

Clin Diagn Virol. 1998 Jul 15;10(2-3):151-6.

PMID:
9741640
20.

Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.

McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE Jr.

Antimicrob Agents Chemother. 1998 Jan;42(1):140-6.

21.

The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme.

Stempniak M, Hostomska Z, Nodes BR, Hostomsky Z.

J Virol. 1997 Apr;71(4):2881-6.

22.

A specific RNA structural motif mediates high affinity binding by the HIV-1 nucleocapsid protein (NCp7).

Allen P, Collins B, Brown D, Hostomsky Z, Gold L.

Virology. 1996 Nov 15;225(2):306-15.

23.

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.

Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z.

Cell. 1996 Oct 18;87(2):331-42.

24.

Development of a nonradioactive ribonuclease H assay.

Rychetsky P, Hostomska Z, Hostomsky Z, Strop P.

Anal Biochem. 1996 Jul 15;239(1):113-5. No abstract available.

PMID:
8660635
25.

What is the orientation of DNA polymerases on their templates?

Hughes SH, Hostomsky Z, Le Grice SF, Lentz K, Arnold E.

J Virol. 1996 May;70(5):2679-83. Review. No abstract available.

26.

Structure-function analysis of the mammalian DNA polymerase beta active site: role of aspartic acid 256, arginine 254, and arginine 258 in nucleotidyl transfer.

Menge KL, Hostomsky Z, Nodes BR, Hudson GO, Rahmati S, Moomaw EW, Almassy RJ, Hostomska Z.

Biochemistry. 1995 Dec 12;34(49):15934-42.

PMID:
8519750
27.

High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus.

Schneider DJ, Feigon J, Hostomsky Z, Gold L.

Biochemistry. 1995 Jul 25;34(29):9599-610.

PMID:
7542922
28.

Comprehensive chemical modification interference and nucleotide substitution analysis of an RNA pseudoknot inhibitor to HIV-1 reverse transcriptase.

Green L, Waugh S, Binkley JP, Hostomska Z, Hostomsky Z, Tuerk C.

J Mol Biol. 1995 Mar 17;247(1):60-8.

PMID:
7534830
29.

Restriction of HIV-1 replication in intestinal cells is genetically controlled by the gag-pol region of the HIV-1 genome.

De Mareuil J, Guettari N, Bolmont C, Salaun D, Baillon JG, Hostomsky Z, Hirsch I.

Virology. 1995 Feb 20;207(1):160-7.

30.

Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates.

Arnold E, Ding J, Hughes SH, Hostomsky Z.

Curr Opin Struct Biol. 1995 Feb;5(1):27-38. Review.

PMID:
7539708
31.

Subunit composition and domain structure of the Spo0A sporulation transcription factor of Bacillus subtilis.

Grimsley JK, Tjalkens RB, Strauch MA, Bird TH, Spiegelman GB, Hostomsky Z, Whiteley JM, Hoch JA.

J Biol Chem. 1994 Jun 17;269(24):16977-82.

32.

2.3 A crystal structure of the catalytic domain of DNA polymerase beta.

Davies JF 2nd, Almassy RJ, Hostomska Z, Ferre RA, Hostomsky Z.

Cell. 1994 Mar 25;76(6):1123-33.

PMID:
8137427
33.

Redesignation of the RNase D activity associated with retroviral reverse transcriptase as RNase H.

Hostomsky Z, Hughes SH, Goff SP, Le Grice SF.

J Virol. 1994 Mar;68(3):1970-1.

34.

M13 and pUC vectors with new unique restriction sites for cloning.

Benes V, Hostomský Z, Arnold L, Paces V.

Gene. 1993 Aug 16;130(1):151-2.

PMID:
8393824
35.
36.
37.

Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase.

Hostomska Z, Matthews DA, Davies JF 2nd, Nodes BR, Hostomsky Z.

J Biol Chem. 1991 Aug 5;266(22):14697-702.

38.

Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase.

Davies JF 2nd, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA.

Science. 1991 Apr 5;252(5002):88-95.

PMID:
1707186
39.
40.

Affinity chromatography with biotinylated RNAs.

Ruby SW, Goelz SE, Hostomsky Z, Abelson JN.

Methods Enzymol. 1990;181:97-121.

PMID:
1696348
41.

High-level expression of self-processed HIV-1 protease in Escherichia coli using a synthetic gene.

Hostomsky Z, Appelt K, Ogden RC.

Biochem Biophys Res Commun. 1989 Jun 30;161(3):1056-63.

PMID:
2662971
42.

Solid-phase assembly of cow colostrum trypsin inhibitor gene.

Hostomský Z, Smrt J, Arnold L, Tocík Z, Paces V.

Nucleic Acids Res. 1987 Jun 25;15(12):4849-56.

43.

Solid-phase assembly of DNA duplexes from synthetic oligonucleotides.

Hostomský Z, Smrt J.

Nucleic Acids Symp Ser. 1987;(18):241-4.

PMID:
3697135
44.

Chloridite and amidite automated synthesis of oligodeoxyribonucleotides using amidine protected nucleosides.

Arnold L, Tocík Z, Bradková E, Hostomský Z, Smrt J.

Nucleic Acids Symp Ser. 1987;(18):181-4.

PMID:
3697123
46.
47.

Cloning and expression in Escherichia coli of the synthetic proenkephalin analogue gene.

Hostomský Z, Smrt J, Paces V.

Gene. 1985;39(2-3):269-74.

PMID:
3937764
48.

Nucleotide sequence of the major early region of Bacillus subtilis phage PZA, a close relative of phi 29.

Paces V, Vlcek C, Urbánek P, Hostomský Z.

Gene. 1985;38(1-3):45-56.

PMID:
3934048
49.

Comparison of Bacillus subtilis phages PZA, phi 29 and phi 15.

Paces V, Hostomský Z, Fucík V, Pivec L, Zadrazil S.

Folia Biol (Praha). 1984;30 Spec No:52-64.

PMID:
6327410
50.

Sequence homology and recombination between the genomes of morphologically dissimilar bacteriophages LP 52 and theta.

Forstová J, Grünnerová H, Hostomský Z, Doskocil J.

Mol Gen Genet. 1982;187(1):138-47.

PMID:
6298569

Supplemental Content

Loading ...
Support Center